Using CRISPR-Cas9 to precisely improve CAR-T cell therapy and change the tumor environment in leukemia

CRISPR-Cas9 technology has transformed genetic engineering, enabling precise genome editing for therapeutic interventions.

• CRISPR-Cas9 allows targeted modifications of immune cells, enhancing their capacity to identify and destroy leukemia cells.
• The technology facilitates the disruption of immune checkpoint inhibitors and the insertion of chimeric antigen receptors (CARs).
• It enables the correction of genetic mutations associated with leukemia progression.
• Advancements in CRISPR-Cas9 have led to more effective and personalized immunotherapies, such as CAR-T cell therapies.
• CRISPR-Cas9 also provides a platform for modeling leukemia in laboratory settings, aiding in the understanding of disease mechanisms.
• While challenges remain, including delivery efficiency and potential immune reactions, CRISPR-Cas9 may redefine treatment standards for leukemia.

Simplified